Finally, it is unknown if these results are generalizable to treatment-naïve patients with acromegaly because all participants in the ACROBAT trials were treated with stable doses of pharmacological treatment and were relatively asymptomatic with only mild elevation of IGF-I levels at study entry. This evidence concerns the gene IGF1 and acromegaly.